-AstraZeneca - BRILINTA monotherapy in high-bleeding risk patients who underwent PCI had reduced risk of clinically relevant bleeding than with dual antiplatelet therapy

Media coverage

• Title	-AstraZeneca - BRILINTA monotherapy in high-bleeding risk patients who underwent PCI had reduced risk of clinically relevant bleeding than with dual antiplatelet therapy
  Media name/outlet	ENP Newswire
  Country/Territory	United Kingdom
  Date	27/09/19
  Persons	Roxana Mehran,